On November 10, 2026, Olema Pharmaceuticals, Inc. announced its financial results for the quarter ending September 30, 2026. This update is significant as it underscores the company's ongoing efforts to advance its innovative cancer therapies while navigating the competitive landscape of the pharmaceutical industry.
Background
Olema Pharmaceuticals, Inc., trading under the ticker OLMA on the Nasdaq exchange, is classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is based in San Francisco, California, and is recognized as a smaller reporting company. Olema is committed to developing targeted therapies for cancer, aiming to address unmet medical needs in oncology.
What the Filing Says
The filing reveals that on November 10, 2026, Olema reported its financial results for the third quarter. The company stated, "A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference." This indicates that additional details regarding their financial performance can be found in the attached press release.
Impact
This update may affect investors, analysts, and stakeholders interested in Olema's financial health and strategic direction. As the company continues to develop its pipeline of cancer therapies, the results reported could influence market perceptions and future investment decisions.
What's Next
The filing does not say what happens next. However, stakeholders may anticipate further updates from Olema as it continues to progress in its research and development efforts.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










